Explore 3 Stock Ideas & Industry Insights Download Free Report

8082-737-676
Shopping Cart 0
countryflagUK
Login

Beam Therapeutics Inc

Healthcare US BEAM

29.55USD
0.59(2.04%)

Last update at 2026-06-03T20:24:00Z

Day Range

28.3029.65
LowHigh

52 Week Range

15.3536.44
LowHigh

Fundamentals

  • Previous Close 28.96
  • Market Cap3153.27M
  • Volume1150406
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-361.39901M
  • Revenue TTM139.74M
  • Revenue Per Share TTM1.41
  • Gross Profit TTM -269.87501M
  • Diluted EPS TTM-0.81

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -79.99200M -376.70300M -131.16100M -260.17800M -370.63800M
Minority interest - - - - -
Net income -79.99200M -376.74200M -132.52700M -263.58800M -341.36000M
Selling general administrative 113.82M 111.53M 116.81M 87.81M 57.22M
Selling and marketing expenses - - 20.01M - -
Gross profit 117.45M -304.04300M 377.71M 60.92M 51.84M
Reconciled depreciation 22.29M 31.59M 18.59M 14.15M 7.45M
Ebit -36.25900M -415.56800M -176.48500M -338.47900M -392.46500M
Ebitda -29.92300M -393.64300M -146.95400M -401.48300M -414.30100M
Depreciation and amortization 6.34M 21.93M 29.53M -63.00400M -21.83600M
Non operating income net other - - - - 21.83M
Operating income -383.69300M -415.56800M -176.48500M -338.47900M -392.46500M
Other operating expenses 523.44M 479.09M 554.19M 399.40M 444.31M
Interest expense 43.73M 49.09M 46.68M 15.30M 0.00900M
Tax provision 0.00000M 0.04M 1.00M 3.41M -
Interest income - - - - -
Net interest income 43.73M 49.09M 42.22M 15.30M -0.00900M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - 0.04M 1.37M 3.41M -29.27800M
Total revenue 139.74M 63.52M 377.71M 60.92M 51.84M
Total operating expenses 501.14M 111.53M 554.19M 399.40M 444.31M
Cost of revenue 22.29M 367.56M 437.38M - -
Total other income expense net 303.70M 38.87M 45.32M 78.30M 21.83M
Discontinued operations - - - - -
Net income from continuing ops -79.99200M -376.74200M -313.67300M -289.08800M -370.63800M
Net income applicable to common shares - - - -260.17800M -370.63800M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1481.18M 1103.82M 1459.71M 1341.71M 1474.45M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 23.48M 27.41M 21.17M 14.76M 307.36M
Total liab 242.82M 370.28M 478.38M 608.24M 647.72M
Total stockholder equity 1238.36M 733.54M 981.33M 733.47M 826.74M
Deferred long term liab - - - - -
Other current liab 65.68M 37.78M 121.98M 68.21M 112.15M
Common stock 1.02M 0.84M 0.82M 0.71M 0.68M
Capital stock 1.02M 0.84M 0.82M 0.71M 0.68M
Retained earnings -1641.21900M -1566.63100M -1189.88900M -1057.36200M -768.27400M
Other liab - - - 214.87M 296.46M
Good will - - - - -
Other assets - - - 14.69M 14.47M
Cash 294.94M 281.97M 435.89M 232.77M 965.65M
Cash and equivalents - - - - -
Total current liabilities 96.94M 182.07M 205.56M 223.59M 213.44M
Current deferred revenue 6.66M 108.86M 68.71M 135.97M 86.27M
Net debt -1.06200M -120.54200M -262.72200M -53.76200M -823.29700M
Short term debt 14.36M 13.47M 13.26M 10.38M 7.54M
Short long term debt - - - - 2.29M
Short long term debt total 293.88M 161.43M 173.17M 179.00M 142.35M
Other stockholder equity 2877.45M 2298.66M 2169.80M 1792.55M 119.92M
Property plant equipment - - - 234.13M 186.98M
Total current assets 1268.69M 878.15M 1211.04M 1092.90M 965.65M
Long term investments - - - - -
Net tangible assets - - - 733.47M 826.74M
Short term investments 950.27M 568.77M 753.98M 845.37M 405.65M
Net receivables - - - 0.00000M 300.00M
Long term debt - - - - 3.01M
Inventory - - - - -607.36000M
Accounts payable 10.23M 3.87M 1.62M 9.03M 7.47M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.11M 0.68M 0.60M -2.43000M -0.05000M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.68M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -768.27400M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.63M 9.40M 2.15M 14.69M 321.83M
Deferred long term asset charges - - - - -
Non current assets total 212.49M 225.68M 248.67M 248.82M 508.81M
Capital lease obligations 154.12M 161.43M 172.69M 179.00M 142.35M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -361.56000M 185.01M 87.18M -461.33600M -247.95300M
Change to liabilities - - - -33.54700M 348.97M
Total cashflows from investing activities -121.43800M 185.01M 71.84M -461.33600M -294.14400M
Net borrowings 0.00000M -0.48500M -2.25200M -2.28700M -2.11800M
Total cash from financing activities 478.05M 7.74M 276.45M 111.59M 756.14M
Change to operating activities - - - -14.82500M -237.72000M
Net income -79.99200M -376.74200M -132.52700M -289.08800M -370.63800M
Change in cash 11.51M -154.50300M 199.09M -327.21900M 395.73M
Begin period cash flow 290.11M 444.61M 245.52M 572.74M 177.01M
End period cash flow 301.62M 290.11M 444.61M 245.52M 572.74M
Total cash from operating activities -345.10200M -347.24600M -149.19500M 22.53M -66.26800M
Issuance of capital stock 470.51M 0.00000M 268.46M 108.26M 757.45M
Depreciation 22.29M 21.93M 20.01M 14.15M 7.45M
Other cashflows from investing activities 254.75M -8.94600M - - 0.62M
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables - - -0.14600M 300.00M -300.00000M
Sale purchase of stock - - - - 758.26M
Other cashflows from financing activities - 8.22M 8.53M 5.62M 0.81M
Change to netincome - - - 16.93M 185.66M
Capital expenditures 14.95M 8.95M 33.73M 48.95M 46.81M
Change receivables - - - - -
Cash flows other operating - - - - 51.89M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - 395.73M
Change in working capital -131.01600M -110.22300M -116.45500M 251.63M 111.25M
Stock based compensation 94.24M 120.66M 98.65M 84.32M 43.57M
Other non cash items -250.63200M -2.86800M -18.87200M -38.48100M 158.86M
Free cash flow -360.04800M -356.19200M -182.92700M -26.42400M -113.07900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
BEAM
Beam Therapeutics Inc		 0.59 2.04% 29.55 - - 22.56 2.59 15.17 -7.0312
NVO
Novo Nordisk A/S		 -0.92 2.14% 42.00 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 -0.75 1.73% 42.50 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 3.25 0.76% 428.34 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 16.03 2.66% 618.95 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targeting lipid nanoparticle (LNP) for the treatment of severe alpha-1 antitrypsin deficiency; BEAM-304, a liver-targeting LNP for the treatment of phenylketonuria; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease type 1a. The company also develops the ESCAPE platform, which combines antibody-based conditioning with multiplex gene edited HSCs. In addition, it develops BEAM-103, an anti-CD117 monoclonal antibody that enables ESCAPE. The company has research collaboration agreement with Pfizer Inc., focusing on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Verve Therapeutics, Inc., for cardiovascular disease treatments; and Orbital Therapeutics to design RNA for the prevention, treatment, or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Beam Therapeutics Inc

238 Main Street, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Mr. John M. Evans M.B.A. CEO & Director 1978
Dr. Giuseppe Ciaramella Ph.D. Pres & Chief Scientific Officer 1969
Ms. Terry-Ann Burrell M.B.A. CFO & Treasurer 1977
Dr. Feng Zhang Ph.D. Co-Founder NA
Dr. David R. Liu Ph.D. Co-Founder NA
Dr. J. Keith Joung M.D., Ph.D. Co-Founder NA
Dr. Nicole Gaudelli Ph.D. Co-Founder NA
Dr. Alexis Komor Ph.D. Co-Founder NA
Ms. Suzanne Fleming Chief Accounting Officer 1961
Mr. Brian Riley Sr. VP of Technical Operations 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions